Niagen Bioscience (NASDAQ:NAGE – Get Free Report) and Beauty Health (NASDAQ:SKIN – Get Free Report) are both small-cap consumer staples companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation and earnings.
Institutional and Insider Ownership
15.4% of Niagen Bioscience shares are held by institutional investors. Comparatively, 93.3% of Beauty Health shares are held by institutional investors. 10.0% of Niagen Bioscience shares are held by company insiders. Comparatively, 35.5% of Beauty Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Risk and Volatility
Niagen Bioscience has a beta of 2.02, meaning that its share price is 102% more volatile than the S&P 500. Comparatively, Beauty Health has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Niagen Bioscience | 12.39% | 17.95% | 13.17% |
| Beauty Health | -9.79% | -47.83% | -5.79% |
Valuation & Earnings
This table compares Niagen Bioscience and Beauty Health”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Niagen Bioscience | $129.08 million | 1.66 | $17.38 million | $0.18 | 14.94 |
| Beauty Health | $290.05 million | 0.25 | -$9.52 million | ($0.22) | -2.50 |
Niagen Bioscience has higher earnings, but lower revenue than Beauty Health. Beauty Health is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Niagen Bioscience and Beauty Health, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Niagen Bioscience | 0 | 1 | 3 | 1 | 3.00 |
| Beauty Health | 1 | 5 | 1 | 0 | 2.00 |
Niagen Bioscience currently has a consensus target price of $10.33, indicating a potential upside of 284.14%. Beauty Health has a consensus target price of $1.38, indicating a potential upside of 150.00%. Given Niagen Bioscience’s stronger consensus rating and higher probable upside, research analysts plainly believe Niagen Bioscience is more favorable than Beauty Health.
Summary
Niagen Bioscience beats Beauty Health on 12 of the 15 factors compared between the two stocks.
About Niagen Bioscience
Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.
About Beauty Health
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.
Receive News & Ratings for Niagen Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Niagen Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
